Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu
Adicet Bio, Inc.
US$138m

Canaccord Genuity Acted as a Co-Manager in a Follow-On Offering for Adicet Bio, Inc.

Transaction Overview:

Adicet Bio, Inc. (the “Company”) (Nasdaq:ACET), priced its $120.0 million public offering on February 10, 2021 at a price of $13.00 per share. The Company issued 9,230,770 shares of common stock. The Underwriters exercised their option to purchase an additional 1,344,743 shares of common stock at a public offering price, bringing the total proceeds to $137.5 million, less the underwriting discounts and commissions.

Company Overview:

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

More like this

 InfraVia Capital Partners
October 2021

InfraVia Capital Partners

Exclusive Financial Adviser
View transaction detail
PharmaCann
October 2021

PharmaCann

Financial Advisor (Buy-side)
View transaction detail
Vicarious Surgical Inc.
US$872m
September 2021

Vicarious Surgical Inc.

Financial/Capital Markets Advisor
View transaction detail